Edition:
United Kingdom

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

4.10USD
14 Dec 2017
Change (% chg)

$-0.05 (-1.20%)
Prev Close
$4.15
Open
$4.15
Day's High
$4.21
Day's Low
$4.07
Volume
164,256
Avg. Vol
210,587
52-wk High
$4.51
52-wk Low
$1.01

Latest Key Developments (Source: Significant Developments)

Great Point Partners Reports 5.14 Pct Passive Stake In Catalyst Pharma
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Catalyst Pharmaceuticals Inc ::GREAT POINT PARTNERS LLC REPORTS A 5.14 PERCENT PASSIVE STAKE IN CATALYST PHARMACEUTICALS INC AS OF NOV 28 - SEC FILING.  Full Article

Catalyst Pharma Announces Proposed Public Offering Of Common Stock
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 11.0 MILLION COMMON SHARES.CATALYST-PLANS TO USE PROCEEDS TO FUND CLINICAL STUDIES OF FIRDAPSE FOR TREATMENT OF MUSK-ANTIBODY POSITIVE MYASTHENIA GRAVIS,SPINAL MUSCULAR ATROPHY​.- PLANS TO USE NET PROCEEDS FROM OFFERING TO FUND PRE-COMMERCIALIZATION ACTIVITIES FOR FIRDAPSE​.  Full Article

Catalyst Pharma Posts Positive Top-Line Results From Second Phase 3 Clinical Trial Of Firdapse
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PHASE 3 CLINICAL TRIAL OF FIRDAPSE® IN PATIENTS WITH LAMBERT-EATON MYASTHENIC SYNDROME.CATALYST PHARMACEUTICALS INC - ‍TREATMENT WITH FIRDAPSE ACHIEVED STATISTICAL SIGNIFICANCE FOR CO-PRIMARY ENDPOINTS AND SECONDARY ENDPOINT​.CATALYST PHARMACEUTICALS INC - ‍POSITIVE RESULTS TO SUPPORT PLANNED NDA SUBMISSION IN Q1 OF 2018​.CATALYST PHARMACEUTICALS INC - ‍FIRDAPSE WAS SAFE AND WELL TOLERATED BY PATIENTS IN TRIAL​.  Full Article

Catalyst Pharmaceuticals posts Q3 loss per share $0.05
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst Pharmaceuticals announces third quarter 2017 financial results and provides corporate update.Q3 GAAP loss per share $0.05.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Catalyst Pharmaceuticals Inc - ‍expects pre-commercialization expenses to increase in Q4 of 2017​.  Full Article

Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse®
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse® in patients with Lambert-Eaton Myasthenic Syndrome.Catalyst Pharmaceuticals Inc - ‍top-line results for Phase 3 trial of Firdapse expected in early December​.  Full Article

Catalyst Pharmaceuticals announce Q2 2016 financial results and provides product development update
Tuesday, 9 Aug 2016 

Catalyst Pharmaceuticals Inc : Catalyst Pharmaceuticals announces second quarter 2016 financial results and provides product development update . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Q2 GAAP loss per share $0.06 .Q2 non-GAAP loss per share $0.06 excluding items.  Full Article

Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse
Monday, 13 Jun 2016 

Catalyst Pharmaceuticals Inc : Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome . Expects to initiate a small, single-center study with Firdapse during second half of 2016 .Existing capital resources are adequate to get us to an accepted NDA submission without need for additional financing.  Full Article

Catalyst Pharmaceuticals announces reduction in workforce
Tuesday, 17 May 2016 

Catalyst Pharmaceuticals Inc : Announces reduction in workforce as part of operating expense management plan . Reducing its workforce by approximately 30% . Expects to complete reduction in workforce immediately . Reduction in workforce affects employees from Catalyst's commercial team . Believe currently available resources will be sufficient to complete development of and refile NDA for firdapse for lems, cms .Reduction in workforce is part of ongoing efforts to conserve cash to complete requirements for NDA submission of Firdapse.  Full Article

Catalyst Pharmaceuticals posts Q1 GAAP loss of $0.07/shr
Tuesday, 10 May 2016 

Catalyst Pharmaceuticals Inc : Believe current resources give sufficient runway for at least next year . Continue to believe available resources will be sufficient to complete development of firdapse, refile nda for firdapse . Catalyst pharmaceuticals announces first quarter 2016 financial results and provides corporate update . Q1 gaap loss per share $0.07 . Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S .Q1 non-gaap loss per share $0.07 excluding items.  Full Article

BRIEF-Great Point Partners Reports 5.14 Pct Passive Stake In Catalyst Pharma

* GREAT POINT PARTNERS LLC REPORTS A 5.14 PERCENT PASSIVE STAKE IN CATALYST PHARMACEUTICALS INC AS OF NOV 28 - SEC FILING Source text for Eikon: (http://bit.ly/2jaVqTo) Further company coverage: